ABSTRACT
The available literature on the pharmacotherapy of rhinitis, conjunctivitis and asthma is vast and to a large degree represents publication of studies sponsored by manufacturers with a vested interest in one or a few products. To assist in assessing this literature we can turn to reviews and meta-analyses, but perhaps the best sources of unbiased information are the national and international guidelines that are evidence-based and written by experts independent of pharmaceutical fi nancial support. Therefore, this chapter of pharmacotherapy will rely heavily on the 2008 Update of the ARIA Guidelines,1 the 2008 Diagnosis and management of rhinitis: An updated practice parameter2 and the 2007 NAEPP/NHLBI Guidelines for the Diagnosis and Management of Asthma.3
